Chee Kay Cheung

机构：University of Leicester, University Hospitals of Leicester NHS Trust · ORCID：0000-0001-8593-7625

发表论文 85 篇 · 总被引 4977 次 · h-index 29

代表论文

• Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial (2021 · The Lancet · 被引 524)
• Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2022 · The Lancet · 被引 384)
• Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis (2022 · The Lancet · 被引 335)
• Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021 · The Lancet · 被引 293)
• Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial (2023 · The Lancet · 被引 226)
• Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy (2022 · Kidney International · 被引 225)